Trainer Rodolphe Brisset said a recent positive test in one of his horses for the prohibited adjunct bleeder medication aminocaproic acid was either a barn or veterinary mistake. The positive test and subsequent disqualification of Talk Veuve to Me from an April 11 allowance/optional claiming race victory at Keeneland in Lexington, Ky., was reported in Daily Racing Form.
Brisset was fined $500 and Talk Veuve to Me's owners, Team Valor International, Stephen McKay and Brisset, were ordered by stewards to forfeit the $51,000 winner's share of the $83,300 purse. Talk Veuve to me, a 4-year-old filly by Violence who won the Grade 3 Indiana Oaks in 2018 and is G1 placed, finished first as the odds-on favorite by 2 ¼ lengths in the April 11 race contested at six furlongs on dirt. Runner-up Treble was elevated to first place.
Better known as Amicar, aminocaproic acid previously had been a permitted race-day medication in a number of states, including Kentucky, whose commission changed its rules in 2012 to only permit the administration of furosemide, or Lasix, within 24 hours of a race. It is a Class 4 drug that calls for a Category C penalty (fine, but no suspension) under Association of Racing Commissioners International guidelines.
This is the first reported medication violation for Brisset, a former assistant to Patrick Biancone and Hall of Fame trainer William Mott. Brisset opened a public stable in 2017 and has won five graded stakes, including the 2019 G2 Oaklawn Handicap with Quip.
Brisset told Daily Racing Form the drug has been used in horses in his stable between races, which is permitted, and that a barn staff or veterinary mistake may have led to the positive, reported by Industrial Laboratories in Wheat Ridge, Colo. “We were already very, very careful, and now we need to be even more careful,” he said. “It's a mistake that cannot be made again.”
Team Valor International, co-owner of the filly, is run by Barry Irwin, an outspoken opponent of race-day medication and supporter of the Water Hay Oats Alliance.
New to the Paulick Report? Click here to sign up for our daily email newsletter to keep up on this and other stories happening in the Thoroughbred industry.
Copyright © 2019 Paulick Report.